Admin
2 June 2024
Dr. Hussein Bagha had the pleasure of being invited to give a talk on CardioRenal Syndrome and Goal-Directed Medical Therapy at the launch of Uperio (Sacubitril/Valsartan) in Mauritius. The event highlighted the significance of addressing the interconnected health challenges faced by patients with both heart failure and kidney injury.
In his presentation, Dr. Bagha emphasized the critical relationship between heart failure and kidney disease. He noted that the incidence of mortality increases significantly when a patient with heart failure also suffers from kidney injury. Furthermore, more than 50% of mortality in patients with chronic kidney disease (CKD) is attributed to cardiovascular disease.
Dr. Bagha underscored the importance of utilizing medications that provide dual benefits to both the heart and kidneys. Uperio (Sacubitril/Valsartan) represents a significant advancement in this regard, offering therapeutic benefits that can improve patient outcomes in cases of CardioRenal Syndrome.
The launch event in Mauritius provided a platform for healthcare professionals to gain insights into the latest advancements in medical therapy for heart and kidney conditions. Dr. Bagha's expertise and dedication to improving patient care were evident in his comprehensive overview of Goal-Directed Medical Therapy and its role in managing CardioRenal Syndrome.
Reflecting on the event, Dr. Bagha expressed his appreciation for the opportunity to share his knowledge and engage with fellow healthcare professionals. He highlighted the importance of ongoing education and collaboration in enhancing the treatment and management of patients with complex conditions involving both the heart and kidneys.
Dr. Bagha's participation in the Uperio launch reinforces his commitment to advancing medical knowledge and improving patient care through innovative therapeutic approaches. His insights into the interplay between cardiovascular and renal health continue to inspire and inform the medical community.
